Reactivation of IgA vasculitis following COVID-19 vaccination.

Autor:	Maye JA; Department of General Medicine, West Suffolk Hospital NHS Foundation Trust, Bury St Edmunds, UK j.anthonymaye@gmail.com., Chong HP; Department of General Medicine, West Suffolk Hospital NHS Foundation Trust, Bury St Edmunds, UK.; Department of Nephrology, West Suffolk Hospital NHS Foundation Trust, Bury St Edmunds, UK., Rajagopal V; Department of General Medicine, West Suffolk Hospital NHS Foundation Trust, Bury St Edmunds, UK.; Department of Rheumatology, West Suffolk Hospital, Bury St Edmunds, UK., Petchey W; Department of General Medicine, West Suffolk Hospital NHS Foundation Trust, Bury St Edmunds, UK.; Department of Nephrology, West Suffolk Hospital NHS Foundation Trust, Bury St Edmunds, UK.
Jazyk:	angličtina
Zdroj:	BMJ case reports [BMJ Case Rep] 2021 Nov 30; Vol. 14 (11). Date of Electronic Publication: 2021 Nov 30.
DOI:	10.1136/bcr-2021-247188
Abstrakt:	A 23-year-old man presented to the acute assessment unit with acute-onset haematuria within 24 hours of receiving his second dose of the Pfizer-BioNTech COVID-19 vaccine. He had been diagnosed with IgA vasculitis 8 months previously. IgA vasculitis is an autoimmune condition characterised by palpable purpura affecting the lower limbs, abdominal pain, arthralgia and renal disease. He was diagnosed with an acute exacerbation of IgA vasculitis and was discharged with oral prednisolone. Reactivation or first presentation of IgA vasculitis is a rare but increasingly recognised complication of COVID-19 vaccination. This is an important new differential in the assessment of patients with haematuria following COVID-19 vaccination. Competing Interests: Competing interests: None declared. (© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu